Home> Products> effective medications therapies

{ "products": [ { "_id": "662cd9d93d1e541c58029df3", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE PIO ", "description": "VILDIABATE PIO \nVildagliptin 50 mg & Pioglitazone Hydrochloride 15 mg\nIntroduction\nType 2 diabetes management often necessitates a multidimensional treatment strategy to effectively control blood glucose levels and reduce the risk of complications. VILDIABATE PIO combines two potent diabetes medications: Vildagliptin (50 mg) and Pioglitazone Hydrochloride (15 mg). This combination leverages the complementary mechanisms of both drugs to offer an enhanced therapeutic effect. This article discusses the benefits, mode of action, and clinical utility of VILDIABATE PIO in the management of Type 2 diabetes.\n\nUnderstanding the Components of VILDIABATE PIO\nVildagliptin (50 mg)\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to regulate blood sugar levels. It works by inhibiting the enzyme DPP-4, which is responsible for breaking down incretin hormones such as GLP-1 and GIP. These hormones play a crucial role in the regulation of glucose metabolism by increasing insulin release and decreasing glucagon secretion in response to meals, thereby aiding in the reduction of postprandial blood glucose levels.\n\nPioglitazone Hydrochloride (15 mg)\nPioglitazone is a type of medication known as a thiazolidinedione, which works primarily by increasing insulin sensitivity in peripheral tissues, such as muscle and fat. It also mildly suppresses hepatic gluconeogenesis. The overall effect is a reduction in insulin resistance, which is a core problem in Type 2 diabetes, making pioglitazone particularly effective for improving glucose control in patients who are insulin resistant.\n\nSynergistic Benefits for Diabetes Management\nEnhanced Glycemic Control\nBy combining Vildagliptin and Pioglitazone, VILDIABATE PIO addresses two major aspects of diabetes management: postprandial glucose spikes and insulin resistance. Vildagliptin improves the incretin system, enhancing pancreatic response to glucose intake, while Pioglitazone works to improve the effectiveness of endogenous insulin. This dual action is effective in reducing both fasting and postprandial blood glucose levels, offering comprehensive glycemic management.\n\nReduced Risk of Hypoglycemia\nVILDIABATE PIO provides a significant advantage in terms of safety. The mechanism of action of both Vildagliptin and Pioglitazone does not inherently cause hypoglycemia as they do not directly stimulate excessive insulin secretion. This makes the combination safer compared to other therapies that might induce hypoglycemia, especially beneficial for elderly patients or those with renal impairment.\n\nBenefits Beyond Glucose Control\nIn addition to controlling blood sugar, Pioglitazone has been shown to have favorable effects on lipid profiles, potentially lowering triglycerides and increasing HDL cholesterol. This cardiovascular risk reduction is an important aspect of diabetes care, given the high risk of heart disease associated with diabetes.\n For further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \nhttps://www.sterisonline.com/product/vildiabate-pio-134257", "price": 295.0, "discountamount": 88.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "fat", "body", "GIP.", "mode", "GLP-1", "EMAIL", "meals", "drugs", "terms", "enzyme", "safety", "muscle", "fasting", "article", "addition", "high risk", "Components", "regulation", "combination", "dual action", "information", "sterisonline", "Introduction", "Vildagliptin", "sterispharma", "crucial role", "Hypoglycemia", "core problem", "Reduced Risk", "heart disease", "CALL/WHATSAPP", "complications", "triglycerides", "effectiveness", "diabetes care", "lipid profiles", "glucose intake", "VILDIABATE PIO", "overall effect", "other therapies", "incretin system", "HDL cholesterol", "natural ability", "glucose control", "insulin release", "important aspect", "elderly patients", "clinical utility", "renal impairment", "DPP-4) inhibitor", "two major aspects", "thiazolidinedione", "incretin hormones", "favorable effects", "glucagon secretion", "peripheral tissues", "blood sugar levels", "glucose metabolism", "endogenous insulin", "insulin resistance", "pancreatic response", "insulin sensitivity", "Synergistic Benefits", "significant advantage", "dipeptidyl peptidase-4", "hepatic gluconeogenesis", "complementary mechanisms", "Enhanced Glycemic Control", "Pioglitazone Hydrochloride", "Type 2 diabetes management", "excessive insulin secretion", "enhanced therapeutic effect", "postprandial glucose spikes", "cardiovascular risk reduction", "two potent diabetes medications", "postprandial blood glucose levels", "comprehensive glycemic management", "multidimensional treatment strategy" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 948, "imageuri": "https://bizimages.withfloats.com/actual/a7e1548775604ef3baba96dfa8adc5cd.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/a7e1548775604ef3baba96dfa8adc5cd.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-27T10:56:25.768Z", "updatedon": "2024-04-27T10:56:25.768Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/vildiabate-pio-/948", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Vildagliptin 50 mg & Pioglitazone Hydrochloride 15 mg", "category": "Diabetic Range", "tags": [ "Vicemic P", "Zomelis P", "Vildax P", "Vylda P", "Pioz-V", "Xilda P" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "662cd367a4eb611de48dd722", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 1000 ", "description": "VILDIABATE M 1000 \nMetformin (1000mg)SR, Vildagliptin (50mg)\nIntroduction\nEffective management of Type 2 diabetes often involves the use of combination therapies that target different aspects of the disease to improve glycemic control. VILDIABATE M 1000 offers an advanced treatment solution by combining Metformin (1000mg) SR (Sustained Release) with Vildagliptin (50mg). This article examines the benefits and mechanisms of action of these two potent agents when used together, highlighting how they provide a synergistic effect to optimize diabetes management.\n\nUnderstanding the Components of VILDIABATE M 1000\nMetformin SR (1000mg)\nMetformin is one of the most prescribed medications for Type 2 diabetes and acts primarily by reducing the production of glucose in the liver, improving insulin sensitivity, and decreasing the intestinal absorption of sugar. The sustained-release formulation of Metformin in VILDIABATE M 1000 helps maintain steady medication levels in the blood, thereby reducing common gastrointestinal side effects and enhancing patient compliance.\n\nVildagliptin (50mg)\nVildagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, which works by blocking the inactivation of incretin hormones. These hormones are released after a meal and increase insulin release and decrease glucagon production based on blood glucose levels. Vildagliptin helps manage the post-meal spikes in blood glucose, which are critical for overall glycemic control.\n\nSynergistic Benefits for Diabetes Management\nEnhanced Glycemic Control\nVILDIABATE M 1000 targets both fasting and postprandial blood glucose levels through its dual-action formula. Metformin addresses the baseline glucose production, while Vildagliptin specifically targets post-meal glucose spikes. This combination provides a comprehensive approach to managing blood sugar levels throughout the day.\n\nReduced Risk of Hypoglycemia\nThe combination of Metformin and Vildagliptin offers a significant advantage in terms of safety. Since both drugs do not typically cause hypoglycemia when used alone, their combination is also associated with a low risk of hypoglycemia compared to other therapies that increase insulin production regardless of blood glucose levels.\n\nWeight Management\nMetformin has been associated with weight loss or weight neutrality in many patients, which is a valuable benefit in diabetes management. Vildagliptin is weight-neutral, ensuring that the combination does not contribute to weight gain, a common concern with some other diabetes medications.\n\nIdeal Candidates for VILDIABATE M 1000\nVILDIABATE M 1000 is particularly suitable for individuals with Type 2 diabetes who:\n\nNeed to control both fasting and postprandial blood glucose levels effectively.\nMay have experienced gastrointestinal side effects with regular metformin.\nAre looking for a combination therapy that minimizes the risk of hypoglycemia.\nRequire a treatment that supports weight management efforts.\nDosage and Administration\nThe typical dosing of VILDIABATE M 1000 involves taking one tablet daily, preferably with a meal to reduce potential gastrointestinal issues and to optimize the absorption of the medications. It is important to follow healthcare guidance closely, as dosages may need to be adjusted based on individual response and kidney function.\nFor further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \nhttps://www.sterisonline.com/product/vildiabate-m-1000-133453\n", "price": 319.0, "discountamount": 95.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "day", "May", "use", "EMAIL", "drugs", "terms", "liver", "1000mg", "Dosage", "safety", "disease", "article", "fasting", "low risk", "mechanisms", "Components", "one tablet", "individuals", "weight loss", "weight gain", "information", "Metformin SR", "VILDIABATE M", "Reduced Risk", "Vildagliptin", "sterisonline", "inactivation", "Hypoglycemia", "sterispharma", "Introduction", "CALL/WHATSAPP", "many patients", "Administration", "typical dosing", "common concern", "Type 2 diabetes", "other therapies", "insulin release", "kidney function", "post-meal spikes", "valuable benefit", "Ideal Candidates", "Sustained Release", "regular metformin", "incretin hormones", "weight neutrality", "different aspects", "two potent agents", "patient compliance", "synergistic effect", "insulin production", "blood sugar levels", "individual response", "combination therapy", "healthcare guidance", "insulin sensitivity", "glucagon production", "dual-action formula", "diabetes management", "Synergistic Benefits", "Effective management", "significant advantage", "combination therapies", "intestinal absorption", "dipeptidyl peptidase-4", "DPP-4) inhibitor class", "comprehensive approach", "steady medication levels", "post-meal glucose spikes", "overall glycemic control", "Enhanced Glycemic Control", "weight management efforts", "other diabetes medications", "advanced treatment solution", "baseline glucose production", "sustained-release formulation", "potential gastrointestinal issues", "postprandial blood glucose levels", "common gastrointestinal side effects" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 945, "imageuri": "https://bizimages.withfloats.com/actual/acabcbb5f8a242cfaa9a96e5bea0480d.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/acabcbb5f8a242cfaa9a96e5bea0480d.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-27T10:28:55.889Z", "updatedon": "2024-04-27T10:28:55.889Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/vildiabate-m-1000-/945", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Metformin (1000mg)SR, Vildagliptin (50mg)", "category": "Diabetic Range", "tags": [ "Zomelis Met", "Vysov-M", "Vildagipt-MF", "Coniglip", "Vilglipt-M", "Valdiff-M", "Glipty M", "Vilcose M", "Vilayo M" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "662cc87084762812b0f61d1e", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIGLICLAGLAZE 30 ", "description": "TRIGLICLAGLAZE 30 \nGliclazide (SR) Pioglitazone and Metformin HCL (SR)\nIntroduction\nThe treatment of Type 2 diabetes demands a comprehensive approach to effectively manage blood glucose levels and prevent long-term complications. TRIGLICLAGLAZE 30 offers a potent combination of Gliclazide (SR), Pioglitazone, and Metformin HCL (SR), providing a multifaceted strategy to tackle various aspects of diabetes management. This article explores the synergistic effects of these medications, their benefits, and the importance of such combination therapies in controlling Type 2 diabetes.\n\nUnderstanding the Components\nGliclazide (SR)\nGliclazide, a sulfonylurea, functions primarily by stimulating the release of insulin from the pancreatic beta cells. It is particularly effective in controlling blood sugar spikes after meals. The sustained release (SR) form of Gliclazide ensures a more gradual release of the medication, which helps in maintaining consistent blood sugar levels throughout the day, while minimizing the risk of hypoglycemia.\n\nPioglitazone\nPioglitazone is a thiazolidinedione that enhances insulin sensitivity in peripheral tissues, such as muscle and fat, and slightly inhibits hepatic gluconeogenesis. This action helps lower insulin resistance, which is a common issue in Type 2 diabetes. Pioglitazone also has benefits for lipid profiles, potentially reducing the risk of cardiovascular complications.\n\nMetformin HCL (SR)\nMetformin, the most commonly prescribed medication for Type 2 diabetes, works by reducing hepatic glucose production and improving insulin sensitivity. The sustained release (SR) formulation provides better gastrointestinal tolerability and a steadier absorption rate, which helps in managing fasting blood glucose levels more effectively.\n\nSynergistic Benefits for Diabetes Management\nComprehensive Glycemic Control\nThe combination of Gliclazide, Pioglitazone, and Metformin in TRIGLICLAGLAZE 30 targets multiple pathways involved in glucose metabolism. Gliclazide addresses postprandial glucose peaks, Pioglitazone improves insulin sensitivity, and Metformin stabilizes basal glucose levels. This comprehensive action helps achieve better overall glycemic control, reducing the risks associated with fluctuating blood sugar levels.\n\nReduced Risk of Hypoglycemia\nWhile Gliclazide could potentially cause hypoglycemia if taken alone, the risk is mitigated by the combination with Metformin and Pioglitazone—both of which do not typically cause low blood sugar levels. This balance provides effective glycemic control without the common side effects associated with high insulin levels.\n\nImproved Insulin Sensitivity and Metabolic Health\nPioglitazone not only assists in reducing blood glucose levels but also helps in improving lipid metabolism and reducing systemic inflammation, which are beneficial for overall metabolic health. The combined effect of these medications can also lead to improvements in weight management, particularly with the inclusion of Metformin.\n\nIdeal Candidates for TRIGLICLAGLAZE 30\nTRIGLICLAGLAZE 30 is suitable for patients with Type 2 diabetes who:\n\nRequire comprehensive management of their blood glucose levels.\nHave not achieved desired control with monotherapy or dual therapy.\nMay benefit from a combination that reduces the risk of cardiovascular diseases.\nDosage and Administration\nThe appropriate dosage of TRIGLICLAGLAZE 30 should be determined by a healthcare provider based on individual patient needs and existing conditions. It is typically taken once daily, which can aid in improving medication adherence due to the convenience of fewer daily doses.\n\nPotential Side Effects and Monitoring\nPatients on TRIGLICLAGLAZE 30 should be monitored for potential side effects, including:\n\nGastrointestinal issues from Metformin, although reduced by the SR formulation.\nWeight gain and fluid retention from Pioglitazone.\nHypoglycemia risk from Gliclazide, though less frequent with the SR formulation.\nRegular monitoring of liver and kidney function is also recommended due to the metabolic pathways affected by these drugs.\nFor further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \nhttps://www.sterisonline.com/product/trigliclaglaze-30-134278", "price": 125.0, "discountamount": 37.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "day", "fat", "meals", "risks", "EMAIL", "drugs", "liver", "muscle", "balance", "article", "patients", "SR) form", "inclusion", "treatment", "importance", "Components", "Gliclazide", "information", "medications", "monotherapy", "Weight gain", "convenience", "improvements", "sterisonline", "dual therapy", "common issue", "sterispharma", "sulfonylurea", "Introduction", "Pioglitazone", "Reduced Risk", "CALL/WHATSAPP", "Metformin HCL", "lipid profiles", "Administration", "SR formulation", "TRIGLICLAGLAZE", "gradual release", "various aspects", "Type 2 diabetes", "combined effect", "kidney function", "fluid retention", "lipid metabolism", "Ideal Candidates", "weight management", "fewer daily doses", "Hypoglycemia risk", "sustained release", "thiazolidinedione", "multiple pathways", "peripheral tissues", "blood sugar spikes", "appropriate dosage", "Regular monitoring", "potent combination", "glucose metabolism", "insulin resistance", "metabolic pathways", "synergistic effects", "existing conditions", "diabetes management", "healthcare provider", "insulin sensitivity", "high insulin levels", "common side effects", "basal glucose levels", "blood glucose levels", "medication adherence", "comprehensive action", "Synergistic Benefits", "systemic inflammation", "pancreatic beta cells", "multifaceted strategy", "combination therapies", "Potential Side Effects", "low blood sugar levels", "comprehensive approach", "Gastrointestinal issues", "long-term complications", "hepatic gluconeogenesis", "cardiovascular diseases", "comprehensive management", "overall metabolic health", "overall glycemic control", "individual patient needs", "steadier absorption rate", "hepatic glucose production", "effective glycemic control", "postprandial glucose peaks", "cardiovascular complications", "gastrointestinal tolerability", "consistent blood sugar levels", "Comprehensive Glycemic Control", "fluctuating blood sugar levels" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 941, "imageuri": "https://bizimages.withfloats.com/actual/9ccf82bc95ff4d2db8ead3ed82734379.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/9ccf82bc95ff4d2db8ead3ed82734379.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-27T09:42:08.312Z", "updatedon": "2024-04-27T09:42:08.312Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/trigliclaglaze-30-/941", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Gliclazide (SR) Pioglitazone and Metformin HCL (SR)", "category": "Diabetic Range", "tags": [ "Glycinorm Total", "Triclazone", "Dianorm Total", "Tricyblex", "Glizid Total P", "Reclimet-PG", "Triglic", "Glz Total", "Bytey Total", "Carryl MP" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "662cc0f518870a17183d4de0", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nAs the landscape of Type 2 diabetes treatment continues to evolve, combining different therapeutic agents to target various pathways has become a key strategy in managing the disease more effectively. TENELIGOLD PIO 20/15, which combines Teneligliptin (20mg) and Pioglitazone (15mg), offers a comprehensive approach to improve glycemic control. This article explores the benefits, mechanisms, and practical usage of this combination therapy, underscoring its potential in enhancing diabetes care.\n\nUnderstanding the Active Ingredients\nTeneligliptin: A Potent DPP-4 Inhibitor\nTeneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by prolonging the action of incretin hormones, which are vital for insulin secretion in response to meals. By inhibiting the enzyme that breaks down these hormones, Teneligliptin allows for increased insulin release and decreased glucagon production, particularly after eating, leading to improved control of postprandial glucose levels.\n\nPioglitazone: A Thiazolidinedione\nPioglitazone falls under the class of thiazolidinediones and primarily works by enhancing insulin sensitivity in peripheral tissue, such as muscle and fat, and inhibiting hepatic gluconeogenesis. This mechanism helps to lower insulin resistance and reduce blood glucose levels. Pioglitazone also has benefits in terms of potentially improving lipid profiles and reducing inflammation.\n\nThe Synergistic Benefits of TENELIGOLD PIO 20/15\nComprehensive Glycemic Control\nThe combination of Teneligliptin and Pioglitazone addresses both insulin secretion and insulin resistance—a dual approach that is often necessary for patients with Type 2 diabetes who experience complex metabolic dysfunctions. This synergy not only helps in achieving better control over fasting and postprandial blood sugar levels but also improves overall metabolic health.\n\nMinimized Risk of Hypoglycemia\nWhile many diabetes treatments increase the risk of hypoglycemia, the combination of Teneligliptin and Pioglitazone carries a lower risk. Teneligliptin enhances insulin secretion in a glucose-dependent manner, reducing the likelihood of insulin-induced hypoglycemia. Pioglitazone does not directly stimulate insulin release, which further mitigates this risk.\n\nPositive Effects on Lipid Profile and Cardiovascular Risk\nPioglitazone has been noted for its beneficial effects on triglycerides and HDL cholesterol levels. When combined with Teneligliptin, TENELIGOLD PIO 20/15 not only manages blood glucose but also contributes to a healthier lipid profile, which is crucial for reducing cardiovascular risk in diabetic patients.\n\nIdeal Candidates for TENELIGOLD PIO 20/15\nThis medication is particularly suitable for Type 2 diabetes patients who:\n\nHave struggled to control blood sugar levels with single-drug therapies.\nAre particularly sensitive to the side effects of other diabetes medications.\nMay benefit from the cardiovascular and lipid profile improvements offered by Pioglitazone.\nDosage and Administration\nTENELIGOLD PIO 20/15 is typically prescribed as one tablet per day, which can be taken with or without food. It is important to monitor liver function before and during treatment with Pioglitazone, as it can affect liver enzymes and requires careful monitoring.\n\nPotential Side Effects and Considerations\nWhile TENELIGOLD PIO 20/15 is effective for many, it does carry potential side effects:\n\nRisk of weight gain and fluid retention, primarily associated with Pioglitazone.\nPotential for increased risk of bone fractures and bladder cancer with long-term use of Pioglitazone.\nMild gastrointestinal issues or respiratory infections related to Teneligliptin.\n For further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \nhttps://www.sterisonline.com/product/teneligold-pio-20-15-134077", "price": 149.0, "discountamount": 44.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "fat", "day", "food", "meals", "terms", "class", "EMAIL", "muscle", "action", "Dosage", "disease", "fasting", "synergy", "article", "response", "improved", "landscape", "mechanisms", "lower risk", "one tablet", "likelihood", "weight gain", "information", "inflammation", "sterisonline", "key strategy", "sterispharma", "Introduction", "Pioglitazone", "dual approach", "long-term use", "CALL/WHATSAPP", "Teneligliptin", "diabetes care", "triglycerides", "liver enzymes", "Minimized Risk", "Considerations", "bladder cancer", "bone fractures", "Administration", "liver function", "increased risk", "teneligold-pio", "lipid profiles", "TENELIGOLD PIO", "fluid retention", "practical usage", "insulin release", "Ideal Candidates", "DPP-4) inhibitor", "Positive Effects", "various pathways", "diabetic patients", "peripheral tissue", "incretin hormones", "insulin secretion", "thiazolidinediones", "Active Ingredients", "beneficial effects", "careful monitoring", "insulin resistance", "combination therapy", "glucagon production", "A Thiazolidinedione", "insulin sensitivity", "Cardiovascular Risk", "blood glucose levels", "single-drug therapies", "Potent DPP-4 Inhibitor", "Potential Side Effects", "HDL cholesterol levels", "comprehensive approach", "respiratory infections", "dipeptidyl peptidase-4", "hepatic gluconeogenesis", "healthier lipid profile", "overall metabolic health", "The Synergistic Benefits", "many diabetes treatments", "glucose-dependent manner", "Type 2 diabetes patients", "Type 2 diabetes treatment", "lipid profile improvements", "other diabetes medications", "postprandial glucose levels", "different therapeutic agents", "insulin-induced hypoglycemia", "Mild gastrointestinal issues", "Comprehensive Glycemic Control", "complex metabolic dysfunctions", "postprandial blood sugar levels" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 938, "imageuri": "https://bizimages.withfloats.com/actual/e2cd2b3d82e941ecbb6ff1c081bd2108.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/e2cd2b3d82e941ecbb6ff1c081bd2108.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-27T09:10:13.536Z", "updatedon": "2024-04-27T09:10:13.536Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/teneligold-pio-20-15-/938", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Teneligliptin & Pioglitazone", "category": "Diabetic Range", "tags": [ "Joten P", "Zita-Pio", "Tenepride P", "Zita Plus-Pio", "Tendia-P", "Tencrine P" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "662b74b7f590fc18c42c0cdf", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "LINALIGLIP M 5/500 ", "description": "LINALIGLIP M 5/500 \nLinagliptin 5mg and Metformin Hydrochloride (SR) 500mg\nIntroduction:\nType 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance and impaired glucose regulation. In the pursuit of effective treatment strategies, combination therapies have emerged as valuable tools for achieving optimal glycemic control while minimizing the risk of adverse effects. LINALIGLIP M 5/500, a formulation containing Linagliptin 5 mg and Metformin Hydrochloride (sustained-release) 500 mg, embodies this approach by combining two proven antidiabetic agents with complementary mechanisms of action. This article delves into the rationale behind the combination, the individual contributions of Linagliptin and Metformin Hydrochloride, and the clinical implications of LINALIGLIP M 5/500 in the management of T2DM.\n\nUnderstanding the Components:\nLINALIGLIP M 5/500 integrates two key components: Linagliptin and Metformin Hydrochloride (SR). Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by enhancing the activity of incretin hormones, such as glucagon-like peptide-1 (GLP-1), thereby stimulating insulin secretion and suppressing glucagon release. Metformin Hydrochloride, a biguanide, primarily acts by reducing hepatic glucose production, increasing peripheral glucose uptake, and improving insulin sensitivity, thus addressing both fasting and postprandial hyperglycemia.\n\nSynergistic Mechanisms of Action:\nThe combination of Linagliptin and Metformin Hydrochloride in LINALIGLIP M 5/500 capitalizes on their complementary modes of action. Linagliptin primarily targets postprandial glucose excursions by enhancing insulin secretion and inhibiting glucagon release. Metformin Hydrochloride, on the other hand, primarily addresses fasting hyperglycemia by reducing hepatic glucose output and improving insulin sensitivity. Together, these medications offer comprehensive glycemic control, targeting multiple aspects of glucose homeostasis.\n\nEfficacy in Glycemic Control:\nClinical studies have demonstrated the efficacy of LINALIGLIP M 5/500 in improving glycemic control in patients with T2DM. The combination therapy has been shown to reduce hemoglobin A1c (HbA1c) levels more effectively than either Linagliptin or Metformin Hydrochloride alone. Additionally, the sustained-release formulation of Metformin Hydrochloride in LINALIGLIP M 5/500 provides prolonged and consistent plasma concentrations, resulting in enhanced tolerability and reduced gastrointestinal side effects compared to immediate-release formulations.\n\nSafety Profile:\nBoth Linagliptin and Metformin Hydrochloride are generally well-tolerated medications with established safety profiles. Common side effects associated with Metformin Hydrochloride may include gastrointestinal symptoms such as nausea, diarrhea, or abdominal discomfort, which are often transient and diminish with continued therapy. Linagliptin, in contrast, is not associated with weight gain or an increased risk of hypoglycemia. By combining these agents in LINALIGLIP M 5/500, clinicians can minimize the risk of adverse effects while optimizing therapeutic efficacy.\nFor further information:\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nBuy Now:\n", "price": 245.0, "discountamount": 73.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "SR", "GLP", "BUY", "T2DM", "risk", "EMAIL", "action", "nausea", "500 mg", "pursuit", "fasting", "reduced", "article", "approach", "diarrhea", "impaired", "patients", "activity", "contrast", "prolonged", "rationale", "biguanide", "other hand", "management", "clinicians", "weight gain", "information", "medications", "LINALIGLIP M", "hypoglycemia", "sterispharma", "sterisonline", "Introduction", "CALL/WHATSAPP", "HbA1c) levels", "hemoglobin A1c", "valuable tools", "Safety Profile", "adverse effects", "Linagliptin 5 mg", "multiple aspects", "Both Linagliptin", "DPP-4) inhibitor", "glucagon release", "Clinical studies", "insulin secretion", "continued therapy", "incretin hormones", "insulin resistance", "two key components", "glucose regulation", "glucose homeostasis", "complementary modes", "insulin sensitivity", "combination therapy", "Common side effects", "abdominal discomfort", "therapeutic efficacy", "clinical implications", "combination therapies", "enhanced tolerability", "dipeptidyl peptidase-4", "hepatic glucose output", "Synergistic Mechanisms", "glucagon-like peptide-1", "Metformin Hydrochloride", "individual contributions", "complementary mechanisms", "Type 2 diabetes mellitus", "optimal glycemic control", "peripheral glucose uptake", "gastrointestinal symptoms", "complex metabolic disorder", "hepatic glucose production", "postprandial hyperglycemia", "sustained-release formulation", "gastrointestinal side effects", "comprehensive glycemic control", "effective treatment strategies", "immediate-release formulations", "two proven antidiabetic agents", "postprandial glucose excursions", "consistent plasma concentrations" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 917, "imageuri": "https://bizimages.withfloats.com/actual/b030c3d3d09044cdb156e98649516547.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/b030c3d3d09044cdb156e98649516547.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-26T09:32:39.587Z", "updatedon": "2024-06-28T12:30:32Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/linaliglip-m-5-500-/917", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Linagliptin 5mg and Metformin Hydrochloride (SR) 500mg", "category": "Diabetic Range", "tags": [ "Trajenta Duo", "Ondero Met", "Linapil-M", "Linaglite M", "Saiumet L", "Ligotil-M", "Nexolina M", "Glylina-M", "Diablin M", "Linanext-M" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 12.0, "isnotforsale": false }, { "_id": "662b5ed6cee634057061560b", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "LINALIGLIP 2.5 ", "description": "LINALIGLIP 2.5 \nLinagliptin 2.5 mg\nIntroduction:\nIn the realm of diabetes management, the advent of novel medications has revolutionized treatment approaches, offering patients more options to effectively manage their condition and improve their quality of life. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has emerged as a prominent player in this landscape. In particular, the formulation known as LINALIGLIP 2.5, featuring Linagliptin 2.5 mg, is gaining attention for its efficacy and safety profile. This article delves into the significance of LINALIGLIP 2.5 in the management of diabetes mellitus.\n\nUnderstanding Linagliptin:\nLinagliptin belongs to the class of medications known as DPP-4 inhibitors, which work by enhancing the levels of incretin hormones, such as glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and decreasing glucagon levels. These actions help regulate blood sugar levels, making Linagliptin an invaluable tool in the management of type 2 diabetes mellitus (T2DM).\n\nKey Features of LINALIGLIP 2.5:\nLINALIGLIP 2.5 is a pharmaceutical formulation of Linagliptin, standardized to contain 2.5 mg of the active ingredient per dose. This dosage strength offers clinicians and patients flexibility in tailoring treatment regimens to individual needs, ensuring optimal glycemic control while minimizing the risk of adverse effects.\n\nEfficacy in Glycemic Control:\nClinical studies have demonstrated the efficacy of Linagliptin, including LINALIGLIP 2.5, in lowering hemoglobin A1c (HbA1c) levels, a key marker of long-term glucose control. By inhibiting DPP-4 activity, Linagliptin helps regulate postprandial glucose levels without increasing the risk of hypoglycemia, making it a valuable adjunct to existing antidiabetic therapies.\n\nSafety Profile:\nOne of the notable advantages of Linagliptin, including LINALIGLIP 2.5, is its favorable safety profile. Unlike some other antidiabetic medications, Linagliptin is not associated with weight gain or an increased risk of hypoglycemia, making it suitable for a wide range of patients, including those who are overweight or at risk of low blood sugar episodes.\n\nConvenience and Compliance:\nThe availability of LINALIGLIP 2.5 in a convenient oral formulation enhances patient compliance with treatment regimens. The once-daily dosing schedule simplifies medication management and fosters adherence, crucial factors in achieving optimal glycemic control and reducing the risk of diabetes-related complications.\n\nCombination Therapy:\nLINALIGLIP 2.5 can be used as monotherapy or in combination with other antidiabetic agents, such as metformin or sulfonylureas, to achieve synergistic effects in glycemic control. Its compatibility with various treatment modalities underscores its versatility in individualized diabetes management strategies.\nFor further information: \n EMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \n BUY NOW\nhttps://www.sterisonline.com/product/linaliglip-2-5-134280\n\n", "price": 205.0, "discountamount": 61.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "BUY", "GLP", "T2DM", "life", "risk", "dose", "EMAIL", "class", "realm", "advent", "product", "article", "quality", "actions", "options", "patients", "efficacy", "adherence", "landscape", "attention", "metformin", "peptide-1", "condition", "increased", "LINALIGLIP", "wide range", "key marker", "clinicians", "Convenience", "monotherapy", "flexibility", "information", "weight gain", "versatility", "availability", "Introduction", "Key Features", "sterisonline", "significance", "hypoglycemia", "sterispharma", "compatibility", "sulfonylureas", "CALL/WHATSAPP", "HbA1c) levels", "DPP-4 activity", "hemoglobin A1c", "crucial factors", "dosing schedule", "invaluable tool", "adverse effects", "dosage strength", "glucagon levels", "DPP-4 inhibitors", "DPP-4) inhibitor", "prominent player", "Clinical studies", "individual needs", "incretin hormones", "insulin secretion", "novel medications", "active ingredient", "treatment regimens", "Linagliptin 2.5 mg", "patient compliance", "notable advantages", "blood sugar levels", "synergistic effects", "Combination Therapy", "treatment approaches", "medication management", "dipeptidyl peptidase-4", "optimal glycemic control", "type 2 diabetes mellitus", "low blood sugar episodes", "favorable safety profile", "long-term glucose control", "other antidiabetic agents", "pharmaceutical formulation", "postprandial glucose levels", "convenient oral formulation", "various treatment modalities", "other antidiabetic medications", "diabetes-related complications", "existing antidiabetic therapies", "individualized diabetes management strategies" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 913, "imageuri": "https://bizimages.withfloats.com/actual/0cddf15cbc19437985a89dea1b69e262.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/0cddf15cbc19437985a89dea1b69e262.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-26T07:59:18.498Z", "updatedon": "2024-04-26T07:59:18.498Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/linaliglip-2-5-/913", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Linagliptin 2.5 mg", "category": "Diabetic Range", "tags": [ "Trajenta", "Ondero", "Linanext", "Linatab", "Linalent", "Dynaglipt L", "Lincreta", "Linasmart", "Glylina" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "661e3eb59166a51f7ccbdbb8", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLISITAPTIN M 50/500 ", "description": "GLISITAPTIN M 50/500 \nSitagliptin Phosphate (50mg) & Metformin HCI (500mg)\nIntroduction to GLISITAPTIN M 50/500\nGLISITAPTIN M 50/500 is an advanced medication designed for the treatment of type 2 diabetes. This combination therapy brings together two potent active ingredients, Sitagliptin Phosphate and Metformin Hydrochloride (HCI), each playing a pivotal role in managing blood sugar levels effectively. This article explores the benefits, mode of action, and essential considerations associated with GLISITAPTIN M 50/500, catering to patients who require a comprehensive approach to diabetes management.\n\nThe Components of GLISITAPTIN M 50/500\n1. Sitagliptin Phosphate (50mg): Sitagliptin Phosphate is a member of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It works by enhancing the body's ability to maintain higher levels of incretin hormones when needed. Incretins help to increase insulin release, especially after a meal, and decrease the amount of sugar made by the liver. The inclusion of 50mg of Sitagliptin in GLISITAPTIN M 50/500 helps in stabilizing post-prandial blood glucose levels.\n\n2. Metformin HCI (500mg): Metformin HCI is one of the most extensively studied diabetes drugs. It primarily works by reducing the production of glucose in the liver, improving the sensitivity of muscle cells to insulin, and therefore helping glucose to enter the cells more effectively. Metformin also has benefits in terms of weight management, making it a valuable component for many diabetics who are also dealing with overweight or obesity issues.\n\nBenefits of GLISITAPTIN M 50/500\nGLISITAPTIN M 50/500 offers several advantages for managing type 2 diabetes. The combination of Sitagliptin and Metformin HCI targets different aspects of diabetes management:\n\nEnhanced Glycemic Control: Together, these medications help to improve blood sugar control more effectively than either component alone, reducing both fasting and postprandial glucose levels.\nWeight Neutral: Unlike some other diabetes medications, Sitagliptin is weight-neutral, meaning it does not contribute to weight gain, which is an essential factor for many patients.\nReduced Risk of Hypoglycemia: Sitagliptin, as part of this combination, contributes to a lower risk of hypoglycemia compared to some other therapies, particularly when used without concurrent sulfonylureas.\nImproved Insulin Sensitivity: Metformin enhances the body’s sensitivity to insulin, helping to lower blood glucose levels more efficiently.\nImportant Considerations\nWhile GLISITAPTIN M 50/500 is highly effective for many individuals, it is not suitable for everyone. Patients with kidney issues or severe heart failure should discuss the risks with their healthcare provider, as Metformin has specific contraindications related to renal function. Additionally, potential side effects such as gastrointestinal upset from Metformin or the rare risk of pancreatitis from Sitagliptin require careful monitoring.\nFor further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \n BUY NOW\nhttps://www.sterisonline.com/product/glisitaptin-m-50-500-133906", "price": 415.0, "discountamount": 124.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "2.", "BUY", "mode", "body", "meal", "50mg", "part", "terms", "liver", "risks", "EMAIL", "amount", "member", "action", "fasting", "ability", "article", "everyone", "benefits", "treatment", "inclusion", "rare risk", "Incretins", "lower risk", "overweight", "production", "Components", "information", "weight gain", "Introduction", "Hypoglycemia", "pancreatitis", "Reduced Risk", "sterispharma", "sterisonline", "pivotal role", "muscle cells", "kidney issues", "CALL/WHATSAPP", "many patients", "higher levels", "GLISITAPTIN M", "Metformin HCI", "many diabetics", "diabetes drugs", "obesity issues", "renal function", "other therapies", "insulin release", "type 2 diabetes", "essential factor", "many individuals", "different aspects", "incretin hormones", "weight management", "several advantages", "blood sugar levels", "careful monitoring", "Insulin Sensitivity", "combination therapy", "blood sugar control", "advanced medication", "diabetes management", "healthcare provider", "severe heart failure", "Sitagliptin Phosphate", "potential side effects", "DPP-4) inhibitor class", "comprehensive approach", "dipeptidyl peptidase-4", "gastrointestinal upset", "Metformin Hydrochloride", "Important Considerations", "essential considerations", "concurrent sulfonylureas", "Enhanced Glycemic Control", "other diabetes medications", "specific contraindications", "postprandial glucose levels", "two potent active ingredients", "post-prandial blood glucose levels" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 908, "imageuri": "https://bizimages.withfloats.com/actual/cf6d16fa025e48f19f17eb0239909460.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/cf6d16fa025e48f19f17eb0239909460.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-16T09:02:45.81Z", "updatedon": "2024-04-16T09:02:45.81Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/glisitaptin-m-50-500-/908", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Sitagliptin Phosphate (50mg) & Metformin HCI (500mg)", "category": "Diabetic Range", "tags": [ "Istamet", "Janumet", "Siglimepol", "Sepamet-XR", "Ulsita M", "Sitamore", "Sitaglanz-M", "Zanvia-M", "Sitapaz M", "Siten-M" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "661e391349be7218fcf4a421", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLISITAPTIN 100 ", "description": "GLISITAPTIN 100 \nSitagliptin Phosphate (100mg)\nOverview of GLISITAPTIN 100\nGLISITAPTIN 100, containing 100mg of Sitagliptin Phosphate, is a prominent medication used in the management of type 2 diabetes. This drug operates as a dipeptidyl peptidase-4 (DPP-4) inhibitor, which means it works by enhancing the body's ability to maintain elevated levels of the hormone incretin. Incretins help to regulate blood sugar by increasing insulin release, especially after a meal, and decreasing the amount of sugar your liver makes.\n\nHow GLISITAPTIN 100 Works\nSitagliptin Phosphate, the active ingredient in GLISITAPTIN 100, plays a crucial role in managing blood sugar levels. It inhibits the enzyme DPP-4, which is responsible for the degradation of incretins. By inhibiting this enzyme, Sitagliptin allows incretins to remain in the blood for a longer period, thus enhancing their effectiveness. This results in increased insulin release in response to meals and a decrease in the glucose produced by the liver.\n\nBenefits of GLISITAPTIN 100 in Managing Type 2 Diabetes\nGLISITAPTIN 100 is highly beneficial for patients with type 2 diabetes who may struggle with controlling their blood sugar levels through diet and exercise alone. One of the key benefits of this medication is its ability to regulate blood sugar without causing significant weight gain—a common side effect of many other diabetes medications. Additionally, GLISITAPTIN 100 is noted for its low risk of causing hypoglycemia (low blood sugar) compared to other therapies.\n\nRecommended Dosage and Administration\nThe typical dose of GLISITAPTIN 100 is one 100mg tablet per day. It is recommended to take the tablet whole, with or without food. Patients should consistently take the medication at the same time each day to maintain the best control over their blood sugar levels. It is important for patients to follow their healthcare provider’s instructions regarding dosage, as it may vary based on individual needs and response to the medication.\n\nPossible Side Effects\nWhile GLISITAPTIN 100 is generally well-tolerated, some individuals may experience side effects. The most common side effects include upper respiratory tract infections, sore throat, and headache. Although rare, there are serious side effects such as pancreatitis, severe joint pain, or allergic reactions, which require immediate medical attention.\n\nInteractions with Other Medications\nGLISITAPTIN 100 can interact with other medications, which can affect how well it or the other medications work. Before starting GLISITAPTIN 100, patients should inform their healthcare provider about all other medications they are taking, including prescription, over-the-counter drugs, and herbal supplements.\nFor further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \n BUY NOW\nhttps://www.sterisonline.com/product/glisitaptin-100-133867\n\n", "price": 495.0, "discountamount": 148.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "BUY", "day", "body", "meal", "food", "diet", "EMAIL", "liver", "amount", "ability", "glucose", "Overview", "response", "decrease", "patients", "exercise", "headache", "low risk", "same time", "Incretins", "management", "GLISITAPTIN", "individuals", "degradation", "sore throat", "information", "sterispharma", "Interactions", "pancreatitis", "instructions", "hypoglycemia", "prescription", "key benefits", "sterisonline", "best control", "crucial role", "typical dose", "enzyme DPP-4", "counter drugs", "longer period", "CALL/WHATSAPP", "effectiveness", "Administration", "elevated levels", "low blood sugar", "other therapies", "insulin release", "individual needs", "DPP-4) inhibitor", "hormone incretin", "one 100mg tablet", "Other Medications", "severe joint pain", "active ingredient", "allergic reactions", "herbal supplements", "blood sugar levels", "Recommended Dosage", "common side effect", "healthcare provider", "prominent medication", "serious side effects", "Possible Side Effects", "Sitagliptin Phosphate", "dipeptidyl peptidase-4", "significant weight gain", "Managing Type 2 Diabetes", "immediate medical attention", "many other diabetes medications", "upper respiratory tract infections" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 907, "imageuri": "https://bizimages.withfloats.com/actual/728beb22f7b04d3492bb54a57ec2ab21.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/728beb22f7b04d3492bb54a57ec2ab21.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-16T08:38:43.207Z", "updatedon": "2024-04-16T08:38:43.207Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/glisitaptin-100-/907", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Sitagliptin Phosphate (100mg)", "category": "Diabetic Range", "tags": [ "Sitalong 100mg Tablet", "Sitaday 100 Tablet", "Suitglip 100 Tablet", "Sitared 100mg Tablet", "Stalix 100 Tablet", "Zensita 100mg Tablet" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "661e32039166a51f7ccbda94", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLISAXAPIN M 5/500 ", "description": "GLISAXAPIN M 5/500 \nSaxagliptin (5mg), Metformin HCI (ER) (500mg)\nSaxagliptin (5mg)\nSaxagliptin is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor used primarily in the management of type 2 diabetes. By inhibiting the enzyme DPP-4, saxagliptin enhances the body's ability to maintain elevated levels of incretins. Incretins are hormones that play a crucial role in the regulation of blood glucose levels. They promote the release of insulin after eating and decrease the production of glucagon by the pancreas when glucose levels are high. This dual action helps in controlling blood sugar levels more effectively.\n\nSaxagliptin’s mechanism allows for a reduction in blood glucose levels without posing a significant risk of causing hypoglycemia (abnormally low blood sugar levels) when used alone. It is especially effective when used in combination with other diabetes medications, such as metformin, making it a versatile option for individuals who may need multiple therapeutic agents to control their diabetes.\n\nMetformin HCI (ER) (500mg)\nMetformin hydrochloride extended-release (ER) is another cornerstone in the treatment of type 2 diabetes, particularly favored for its effectiveness, safety profile, and affordability. As a biguanide class medication, metformin primarily works by reducing glucose production in the liver, improving the body's sensitivity to insulin, and facilitating the uptake of glucose by the muscles. This extended-release formulation ensures a steady absorption and a prolonged effect, which helps in maintaining consistent blood sugar levels throughout the day.\n\nOne of the significant benefits of metformin ER is its ability to minimize gastrointestinal side effects commonly associated with the immediate-release formulations. This feature makes it more tolerable for patients, increasing the likelihood of adherence to the medication regimen.\n\nGLISAXAPIN M 5/500\nCombining 5 mg of saxagliptin and 500 mg of metformin HCI in an extended-release formulation, GLISAXAPIN M 5/500 is designed to offer a synergistic effect in the management of type 2 diabetes. This combination therapy enhances the control of blood glucose levels while mitigating the risk of side effects associated with high dosages of a single medication.\n\nGLISAXAPIN M 5/500 provides the benefits of both saxagliptin and metformin ER. Saxagliptin works by enhancing the body’s natural ability to control high blood sugar and increasing insulin production after meals. On the other hand, metformin ER reduces the liver’s sugar production and improves insulin sensitivity. This dual mechanism is particularly beneficial for patients who have not achieved their target blood sugar levels with single-agent therapy.\n\nAdvantages of GLISAXAPIN M 5/500:\nEnhanced Glycemic Control: The combination of saxagliptin and metformin ER in GLISAXAPIN M 5/500 helps in achieving better control over blood glucose levels, which is essential for the prevention of diabetes-related complications.\nReduced Risk of Hypoglycemia: Unlike other combination therapies that might include sulfonylureas, GLISAXAPIN M 5/500 carries a lower risk of hypoglycemia, making it a safer choice for elderly patients or those at risk of low blood sugar episodes.\nConvenience in Dosage: The extended-release formulation allows for once-daily dosing, which is easier for patients to manage and helps improve adherence to the treatment regimen.\nImproved Tolerability and Patient Compliance: The combination reduces the likelihood of gastrointestinal side effects, a common barrier to metformin therapy, thus improving overall patient comfort and compliance with long-term therapy.\nFor further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \n BUY NOW\nhttps://www.sterisonline.com/product/glisaxapin-m-5-500-133434", "price": 194.0, "discountamount": 58.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "day", "BUY", "body", "5 mg", "EMAIL", "liver", "meals", "uptake", "dosing", "500 mg", "feature", "muscles", "pancreas", "glucagon", "hormones", "adherence", "reduction", "incretins", "prevention", "lower risk", "Advantages", "management", "other hand", "regulation", "likelihood", "Convenience", "information", "cornerstone", "dual action", "individuals", "Saxagliptin", "metformin ER", "Reduced Risk", "GLISAXAPIN M", "hypoglycemia", "safer choice", "sterisonline", "sterispharma", "high dosages", "crucial role", "enzyme DPP-4", "effectiveness", "CALL/WHATSAPP", "Metformin HCI", "sulfonylureas", "affordability", "common barrier", "safety profile", "dual mechanism", "elevated levels", "type 2 diabetes", "natural ability", "significant risk", "high blood sugar", "sugar production", "DPP-4) inhibitor", "prolonged effect", "elderly patients", "versatile option", "single medication", "treatment regimen", "steady absorption", "metformin therapy", "long-term therapy", "glucose production", "medication regimen", "insulin production", "Patient Compliance", "synergistic effect", "combination therapy", "insulin sensitivity", "significant benefits", "single-agent therapy", "blood glucose levels", "Improved Tolerability", "low blood sugar levels", "overall patient comfort", "low blood sugar episodes", "Enhanced Glycemic Control", "target blood sugar levels", "other diabetes medications", "biguanide class medication", "multiple therapeutic agents", "other combination therapies", "extended-release formulation", "potent dipeptidyl peptidase-4", "consistent blood sugar levels", "gastrointestinal side effects", "immediate-release formulations", "diabetes-related complications", "Metformin hydrochloride extended-release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 905, "imageuri": "https://bizimages.withfloats.com/actual/99230867942149c48b20d000ea41d2d6.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/99230867942149c48b20d000ea41d2d6.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-16T08:08:35.576Z", "updatedon": "2024-04-16T08:08:35.576Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/glisaxapin-m-5-500-/905", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Saxagliptin (5mg), Metformin HCI (ER) (500mg)", "category": "Diabetic Range", "tags": [ "Kombiglyze", "Riax-M", "Zaxaglit M", "Zaglivia M" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false }, { "_id": "661d1ee52e9ec00d2cc6d5a3", "fptag": "STERISHEALTHCAREPVTLTDADA8", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIDAPAFLOZIN M 5/500 ", "description": "GLIDAPAFLOZIN M 5/500\nDapagliflozin (5mg), Metformin (500mg)\nDapagliflozin (5mg)\nDapagliflozin, a pivotal component of GLIDAPAFLOZIN M 5/500, belongs to a class of medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. This innovative drug works by helping the kidneys to remove glucose from the bloodstream through urine. As a result, it lowers blood sugar levels in adults with type 2 diabetes, making it an essential tool in diabetes management.\n\nThe 5mg dosage of Dapagliflozin in GLIDAPAFLOZIN M 5/500 ensures that it is effective yet gentle, minimizing the risk of side effects commonly associated with higher doses. The drug's action does not depend on insulin release, which is beneficial for patients whose pancreas does not produce sufficient insulin.\n\nMoreover, Dapagliflozin has shown additional health benefits, such as reducing blood pressure and aiding weight loss. These effects are highly advantageous as they address the often co-occurring issues in diabetic patients, such as hypertension and obesity.\n\nMetformin (500mg)\nMetformin, the other active ingredient in GLIDAPAFLOZIN M 5/500, is a well-established medication in the treatment of type 2 diabetes, known for its effectiveness, safety, and cost-efficiency. At a 500mg dosage, it provides a solid foundation for glucose management without contributing significantly to hypoglycemia or weight gain, which are common concerns with other diabetes medications.\n\nThe primary mechanism of Metformin involves reducing the production of glucose in the liver, increasing insulin sensitivity, and enhancing glucose uptake by the muscles. This multipronged approach makes Metformin an excellent base for combination therapies like GLIDAPAFLOZIN M 5/500, where it complements the glucose-lowering effects of Dapagliflozin.\n\nPatients taking Metformin also benefit from its protective aspects concerning cardiovascular health. Studies suggest that Metformin can decrease LDL (bad) cholesterol and triglyceride levels, further protecting against heart disease, which is a frequent complication in diabetes patients.\n\nConclusion\nGLIDAPAFLOZIN M 5/500 combines the strengths of Dapagliflozin and Metformin, offering a dual mechanism of action in the management of type 2 diabetes. This combination not only effectively reduces blood sugar levels but also addresses other health concerns like weight management and cardiovascular health. The inclusion of 5mg of Dapagliflozin and 500mg of Metformin in this formulation ensures efficacy while maintaining a high safety profile.\n\nFor patients and healthcare providers looking for an effective, safe, and comprehensive diabetes treatment, GLIDAPAFLOZIN M 5/500 offers a promising solution. By managing blood sugar levels and providing additional health benefits, this medication supports a holistic approach to diabetes care, significantly enhancing the quality of life for those affected by this chronic condition.\nFor further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 \n BUY NOW\nhttps://www.sterisonline.com/product/glidapaflozin-m-5-500-133424\n\n", "price": 128.0, "discountamount": 38.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 0, "_keywords": [ "BUY", "life", "risk", "class", "EMAIL", "liver", "urine", "action", "adults", "result", "kidneys", "muscles", "Studies", "obesity", "quality", "pancreas", "efficacy", "strengths", "Metformin", "inclusion", "production", "Conclusion", "5mg dosage", "bloodstream", "weight gain", "information", "formulation", "weight loss", "500mg dosage", "hypertension", "side effects", "hypoglycemia", "sterisonline", "sterispharma", "higher doses", "heart disease", "CALL/WHATSAPP", "transporter 2", "Dapagliflozin", "diabetes care", "effectiveness", "sodium-glucose", "blood pressure", "glucose uptake", "essential tool", "excellent base", "dual mechanism", "insulin release", "type 2 diabetes", "common concerns", "GLIDAPAFLOZIN M", "cost-efficiency", "innovative drug", "occurring issues", "solid foundation", "diabetes patients", "diabetic patients", "pivotal component", "weight management", "chronic condition", "holistic approach", "SGLT2) inhibitors", "primary mechanism", "blood sugar levels", "glucose management", "sufficient insulin", "promising solution", "protective aspects", "triglyceride levels", "insulin sensitivity", "diabetes management", "high safety profile", "healthcare providers", "LDL (bad) cholesterol", "combination therapies", "other health concerns", "multipronged approach", "cardiovascular health", "frequent complication", "other active ingredient", "glucose-lowering effects", "additional health benefits", "other diabetes medications", "comprehensive diabetes treatment" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 902, "imageuri": "https://bizimages.withfloats.com/actual/b1829297ad75491fbe0af5035be220c9.jpg", "tileimageuri": "https://bizimages.withfloats.com/actual/b1829297ad75491fbe0af5035be220c9.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-15T12:34:45.23Z", "updatedon": "2024-04-15T12:34:45.23Z", "buyonlinelink": null, "producturl": "https://www.sterispharma.com/medicines/glidapaflozin-m-5-500-/902", "availableunits": -1.0, "iscodavailable": true, "isprepaidonlineavailable": true, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Dapagliflozin (5mg), Metformin (500mg)", "category": "Diabetic Range", "tags": [ "Xigduo", "Dapaturn M", "Zucapride-M", "Dapaease M", "Gliflosal M", "SBdapa M", "Daplo M", "Dapacose-M", "Dapzigard M Forte", "Dapixa DM" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "AssuredPurchase", "producttype": "products", "hsncode": "", "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 10, "query": null, "floatingpoint": null }